Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 2/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12132457 | 0.86 | KDM4E (0.56) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL6006410 | 0.85 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL13951132 | 0.83 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL6756547 | 0.83 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL9468163 | 0.83 | SLC1A3 (0.64) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL24541928 | 0.82 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL20025843 | 0.81 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL6006460 | 0.78 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL6006448 | 0.78 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL810061 | 0.77 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-0644182-B1 | Cyclohexane derivatives useful as potassium channel openers | EISAI CO LTD (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-5605907-A | USEFUL AS A PREVENTIVE AND THERAPEUTIC AGENT FOR DISEASES AGAINST WHICH A POTASSIUM CHANNEL OPENING ACTION IS EFFICACIOUS | EISAI CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5478839-A | Potassium channel modulator, bronchodilator agent, muscle relaxants, vasodilator | EISAI CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0644182-A1 | Cyclohexane derivatives useful as potassium channel openers | Eisai Co., Ltd. (JP) | 1995-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | SLC1A3 2390/4885SLC1A2 2008/4885SLC1A1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.